Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

BACKGROUND: Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A ph...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Epigenetics
Auteurs principaux: Tsujikawa, Laura M., Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D., Stotz, Stephanie C., Sarsons, Christopher D., Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6626370/
https://ncbi.nlm.nih.gov/pubmed/31300040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0696-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires